Lineage Cell Therapeutics Inc (LCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $231.35M
Last updated: Nov 17, 2026 at 11:06 AM ET
Lineage Cell Therapeutics Inc (LCTX) Financials: Revenue, Profit and Cash Flow
Lineage Cell Therapeutics reported revenue of $14.56M for the fiscal year ended Dec 31, 2025, up 53.2% from the year before. That year, net income was -$63.37M with a net margin of -435.3%, operating cash flow was -$18.92M and free cash flow was -$19.44M. The quarter ended Sep 30, 2026 had revenue of $1.43M and net income of $4.23M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $5.92M, a compound annual rate of 10.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $14.56M | +53.2% | 99.0% | -251.6% | -435.3% |
| Dec 2024 | $9.50M | +6.2% | 96.5% | -226.1% | -195.6% |
| Dec 2023 | $8.95M | -39.2% | 92.5% | -276.5% | -240.1% |
| Dec 2022 | $14.70M | +238.7% | 95.0% | -153.2% | -179.2% |
| Dec 2021 | $4.34M | +137.7% | 67.2% | -1133.6% | -996.8% |
| Dec 2020 | $1.83M | -48.1% | 78.9% | -1448.4% | -1132.8% |
| Dec 2019 | $3.52M | -29.5% | 88.3% | -1106.0% | -336.5% |
| Dec 2018 | $4.99M | +44.2% | 93.9% | -837.9% | -937.9% |
| Dec 2017 | $3.46M | -41.6% | 95.1% | -1125.0% | -673.5% |
| Dec 2016 | $5.92M | N/A | 94.0% | -995.6% | 314.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.56M | $9.50M | $8.95M | $14.70M | $4.34M | $1.83M | $3.52M | $4.99M | $3.46M | $5.92M |
| Cost of revenue | $146.00K | $334.00K | $671.00K | $728.00K | $1.43M | $385.00K | $412.00K | $302.00K | $168.00K | $358.00K |
| Gross profit | $14.41M | $9.16M | $8.27M | $13.97M | $2.92M | $1.44M | $3.10M | $4.69M | $3.29M | $5.57M |
| Research and development | $17.73M | $12.47M | $15.71M | $13.99M | $33.91M | $12.32M | $17.95M | $21.75M | $24.02M | $36.11M |
| Operating income | -$36.62M | -$21.48M | -$24.73M | -$22.52M | -$49.21M | -$26.45M | -$38.88M | -$41.80M | -$38.90M | -$58.97M |
| Net income | -$63.37M | -$18.58M | -$21.48M | -$26.35M | -$43.27M | -$20.68M | -$11.83M | -$46.78M | -$23.29M | $18.62M |
| EBITDA | N/A | -$19.69M | -$24.22M | N/A | -$43.13M | -$21.05M | -$26.34M | N/A | N/A | -$19.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.43M | $1.07M | $1.73M | $6.61M | $3.68M | $2.77M | $1.50M | $2.87M | $3.78M | $1.41M | $1.44M | $2.09M |
| Gross profit | $1.43M | $1.07M | $1.73M | $6.54M | $3.68M | $2.73M | $1.47M | $2.71M | $3.74M | $1.36M | $1.35M | $1.83M |
| Operating income | -$7.31M | -$8.92M | -$7.59M | -$6.55M | -$3.79M | -$19.78M | -$6.50M | -$5.11M | -$3.84M | -$5.87M | -$6.66M | -$6.36M |
| Net income | $4.23M | $1.54M | -$4.79M | $892.00K | -$29.75M | -$30.36M | -$4.14M | -$3.25M | -$3.00M | -$5.77M | -$6.56M | -$4.71M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $37.00K by $40.75M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $112.58M | $113.22M | $101.02M | $123.66M | $174.54M | $107.95M | $125.48M | $101.66M | $173.24M | $142.57M |
| Current assets | $59.16M | $51.00M | $38.44M | $60.00M | $111.55M | $44.00M | $57.52M | $36.36M | $42.62M | $25.65M |
| Cash and equivalents | $40.79M | $45.79M | $35.44M | $11.36M | $55.74M | $32.59M | $9.50M | $23.59M | $36.84M | $22.09M |
| Total liabilities | $69.24M | $36.21M | $39.00M | $51.73M | $83.65M | $12.82M | $14.23M | $9.41M | $8.98M | $12.06M |
| Short-term debt | $37.00K | $55.00K | $52.00K | $36.00K | $831.00K | $16.00K | $1.22M | $70.00K | $364.00K | $1.13M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $104.00K | $18.00K | $1.15M |
| Shareholder equity | $44.55M | $78.38M | $63.42M | $73.34M | $92.22M | $96.20M | $112.96M | $93.84M | $162.64M | $117.93M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $100.11M | $106.22M | $109.53M | $112.58M | $89.64M | $90.80M | $111.75M | $113.22M | $96.59M | $102.80M | $108.48M | $101.02M |
| Total liabilities | $34.17M | $46.42M | $56.84M | $69.24M | $68.84M | $43.69M | $34.10M | $36.21M | $31.80M | $35.93M | $37.49M | $39.00M |
| Cash and equivalents | $26.50M | $37.35M | $35.94M | $40.79M | $40.46M | $42.27M | $47.89M | $45.79M | $27.75M | $29.62M | $43.58M | $35.44M |
| Shareholder equity | $67.06M | $60.92M | $53.88M | $44.55M | $22.04M | $48.38M | $79.03M | $78.38M | $66.19M | $68.30M | $72.40M | $63.42M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.92M | -$23.09M | -$28.57M | $1.06M | -$23.56M | -$19.75M | -$31.95M | -$30.88M | -$30.52M | -$42.33M |
| Capital expenditures | $522.00K | $565.00K | $674.00K | $413.00K | $340.00K | $64.00K | $440.00K | $1.42M | $1.33M | $2.53M |
| Free cash flow | -$19.44M | -$23.66M | -$29.24M | $646.00K | -$23.90M | -$19.82M | -$32.39M | -$32.30M | -$31.84M | -$44.85M |
| Dividends paid | N/A | N/A | $37.00K | N/A | $7.24M | $25.15M | $40.00K | $34.41M | $454.00K | N/A |
| Share repurchases | N/A | N/A | $0 | $106.00K | N/A | N/A | N/A | N/A | $0 | N/A |
| Investing cash flow | -$13.46M | -$2.31M | $46.45M | -$46.16M | $9.74M | $13.04M | $16.96M | $11.82M | -$10.22M | -$10.89M |
| Financing cash flow | $26.95M | $35.86M | $6.42M | $1.63M | $36.93M | $29.86M | $617.00K | $5.77M | $55.39M | $32.78M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.62M | -$7.24M | -$8.08M | -$4.88M | -$3.62M | -$5.54M | -$4.89M | -$6.35M | -$5.79M | -$5.18M | -$5.78M | -$6.02M |
| Capital expenditures | $74.00K | $108.00K | $55.00K | $399.00K | $12.00K | $14.00K | $97.00K | $365.00K | $112.00K | $50.00K | $38.00K | $91.00K |
| Free cash flow | -$5.69M | -$7.35M | -$8.13M | -$5.28M | -$3.63M | -$5.55M | -$4.98M | -$6.71M | -$5.90M | -$5.23M | -$5.82M | -$6.11M |
Frequently Asked Questions About LCTX
What is Lineage Cell Therapeutics' annual revenue?
Lineage Cell Therapeutics reported revenue of $14.56M for the fiscal year ended Dec 31, 2025.
How fast is Lineage Cell Therapeutics' revenue growing?
Revenue was up 53.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.
Is Lineage Cell Therapeutics profitable?
No. Lineage Cell Therapeutics reported net income of -$63.37M for the fiscal year ended Dec 31, 2025, with a net margin of -435.3%.
How much free cash flow does LCTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.92M minus capital expenditures of $522.00K produced free cash flow of -$19.44M.
How much debt does Lineage Cell Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $37.00K and cash and equivalents of $40.79M.
LCTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors